Vimukt Dave And Sohini Das

Stories by Vimukt Dave And Sohini Das

Why Jio may now have to buy spectrum from the open market

Why Jio may now have to buy spectrum from the open market

Rediff.com   20 Apr 2019

While the company insisted it had enough spectrum across circles, analysts said the company might soon need to acquire some spectrum to ensure uninterrupted service.

Raymond forays into real estate with Thane project

Raymond forays into real estate with Thane project

Rediff.com   4 Apr 2019

The project will house 3,000 residential units across 10 towers in the first phase on a 20-acre land parcel that Raymond owns in Thane

Why cold wave across US is good news for Indian drug cos

Why cold wave across US is good news for Indian drug cos

Rediff.com   12 Mar 2019

Companies such as Cadila Healthcare, Lupin, and Natco, which sell generic versions of flu medication in the US market, are likely to benefit.

Jio likely to grab 51% revenue market share in 3 years

Jio likely to grab 51% revenue market share in 3 years

Rediff.com   7 Jan 2019

Airtel and Vodafone Idea are also trying to expand the penetration of 4G users in their subscriber base as they take this network to the hinterland

As shares plunge to 5-year low, Sun Pharma promoters poorer by Rs 12,660 crore in 10 days

As shares plunge to 5-year low, Sun Pharma promoters poorer by Rs 12,660 crore in 10 days

Rediff.com   6 Dec 2018

Sun Pharma's market capitalisation stood at Rs 100,050 crore on December 5, with its share price closing at Rs 417 a piece - lowest since March 2013.

Bhavdeep Singh, the CEO who championed organ donation quits Fortis

Bhavdeep Singh, the CEO who championed organ donation quits Fortis

Rediff.com   9 Nov 2018

Singh, who was instrumental in building required capabilities in the organisation said his role at Fortis did not allow him to spend time with his family, as the reason behind his resignation.

J&J's loss may be good news for Indian pharmas

J&J's loss may be good news for Indian pharmas

Rediff.com   1 Nov 2018

Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga

Why drug firms' Q2 revenue growth is likely to dip

Why drug firms' Q2 revenue growth is likely to dip

Rediff.com   12 Oct 2018

Currency played an important role in Q2, with US dollar, Japanese yen and euro appreciating vis-a-vis the Indian rupee, while the Brazilian real, South African rand and Russian ruble depreciating against rupee.

Quality perceptions hobble Jan Aushadi drugs

Quality perceptions hobble Jan Aushadi drugs

Rediff.com   10 Oct 2018

Large pharmaceutical firms feel that if the quality parameters and assurance levels are brought up to the level of branded generics, then Jan Aushadhi medicines would find it difficult to retain their affordability.

Why draft pharma policy may take time to see light of day

Why draft pharma policy may take time to see light of day

Rediff.com   25 Sep 2018

Some of the proposals (for example trade margin calculation for imported medical devices) were not approved by the PMO and were sent back for revisions.

How Amul is quelling the 'non-veg' rumours

How Amul is quelling the 'non-veg' rumours

Rediff.com   21 Sep 2018

This is not the first time Gujarat Cooperative Milk Marketing Federation that owns brand Amul has chosen an unconventional method to protect its brand.

For Singh brothers, truce is temporary, split only way out

For Singh brothers, truce is temporary, split only way out

Rediff.com   15 Sep 2018

NCLT allows Shivinder to withdraw petition against his brother Malvinder. Final decision to be taken by family members in their presence.

Shivinder vs Malvinder: Mother helps avoid legal battle for now

Shivinder vs Malvinder: Mother helps avoid legal battle for now

Rediff.com   14 Sep 2018

Sources said she had stopped eating for the past few days and had constantly been making calls and sending emails to the two brothers.

Faulty hip implants: Centre to ask J&J to compensate victims

Faulty hip implants: Centre to ask J&J to compensate victims

Rediff.com   30 Aug 2018

Once the patients are identified, the government will decide on the quantum of compensation in each case and then approach J&J for claim settlement.

How Manipal plans to spread its wings in India

How Manipal plans to spread its wings in India

Rediff.com   16 Aug 2018

Rough estimates show that at a rate of Rs 1 crore per hospital bed, the investment in India alone would be around Rs 2,000 crore

Over 340 drugs to go off the shelves soon

Over 340 drugs to go off the shelves soon

Rediff.com   26 Jul 2018

Some of the popular brands that would be impacted include Phensedyl (Abbott), Tixylix (Abbott), Gluconorm PG (Lupin), Ascoril D (Glenmark), Solvin Cold (Ipca), D Cold Total (Paras Pharma).

How Fortis Healthcare's fortunes will change post acquisition by IHH

How Fortis Healthcare's fortunes will change post acquisition by IHH

Rediff.com   16 Jul 2018

In its investor presentation, IHH said it wanted to develop Fortis into a market leader.

Why govt's drive to promote generic drugs is flawed

Why govt's drive to promote generic drugs is flawed

Rediff.com   15 Jun 2018

Experts believe the move will have little impact given limited production of generic drugs and authority of doctors in prescribing medicines.

Pharma industry bounces back to good health

Pharma industry bounces back to good health

Rediff.com   12 Jun 2018

In May, price growth for drugs was in negative territory at (-)1 per cent

Why Modi's dream of starting bullet train by 2022 may be derailed

Why Modi's dream of starting bullet train by 2022 may be derailed

Rediff.com   21 May 2018

While farmers in Gujarat are rejecting the compensation package, farmers in Maharashtra say they do not wish to part with their land for a project that largely benefits Gujarat.